Loading...
•
Dec 31, 2020
NextCure Q4 2020 Earnings Report
NextCure reported fourth quarter and full year 2020 financial results and provided a business update.
Key Takeaways
NextCure reported its Q4 and full year 2020 financial results, highlighting the advancement of its programs despite the COVID-19 pandemic and the expansion of its pipeline with NC762.
NC318 is being re-explored for lung cancer treatment through an investigator-initiated trial at Yale University.
The NC410 Phase 1 trial is advancing, with initial data expected in the second half of the year.
NC762, a B7-H4 antibody, is expected to enter the clinic next quarter.
Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditure requirements into the second half of 2023.
Forward Guidance
NextCure anticipates its current financial resources will sustain operations into the second half of 2023, based on current research and development plans.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...